Tengion's platform technologies are applicable to the development of a variety of innovative product candidates for the treatment of organ and tissue impairment, failure and loss. Tengion is developing additional autologous neo-organs and tissues that harness the body's ability to regenerate.
Based upon the principles demonstrated with the Tengion Neo-Bladder Augment™ and Tengion Neo-Urinary Conduit™, Tengion is developing gastrointestinal product candidates.
Tengion’s Neo-GI Augment™ is being developed with the goal of using a patient’s own cells to build gastrointestinal solutions for patients who have a need for esophageal or intestinal tissue.
Tengion’s gastrointestinal programs are not yet in clinical development and are not commercially available.